- Home
- STRO
STRO
Sutro Biopharma Inc.
as 09-13-2024 11:44am EST
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 377.9M | IPO Year: | 2018 |
| Target Price: | $12.13 | AVG Volume (30 days): | 610.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.01 - $6.13 | Next Earning Date: | 11-11-2024 |
| Revenue: | $169,359,000 | Revenue Growth: | 197.83% |
| Revenue Growth (this year): | -56.17% | Revenue Growth (next year): | -3.61% |
Latest Sutro Biopharma Inc. News
STRO Breaking Stock News: Dive into STRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
GlobeNewswire
4 days ago
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Zacks
20 days ago
Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Clinical Trials Arena
23 days ago
Sutro Biopharma commences Phase II trial of luvelta for lung cancer
MT Newswires
24 days ago
Sutro Biopharma Initiates Phase 2 Trial of Luvelta in Non-Small Cell Lung Cancer
GlobeNewswire
24 days ago
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
MT Newswires
a month ago
Truist Securities Adjusts Price Target on Sutro Biopharma to $15 From $18, Maintains Buy Rating
Simply Wall St.
a month ago
Companies Like Sutro Biopharma (NASDAQ:STRO) Are In A Position To Invest In Growth
Compare STRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STRO Sutro Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.